TMEM176A drives anti-apoptotic signaling through TGM2-mediated ERK activation in gastric cancer.

Lipidomic machine learning predictor for progression of gastric cancer.

Inner filter effect regulated upconversion sensing platform for non-invasive detection of two gastric cancer relevant substances.

Traditional Chinese medicine has been widely used to treat gastric cancer, but the effect of the Weinaian capsule on gastric cancer is still unclear. This study aimed to find the potential therapeutic targets and pharmacological mechanisms of Weinaian capsule in gastric cancer. We employed the network pharmacological analysis to find the therapeutic targets. Firstly, we searched the bioactive components of Weinaian capsule in TCMSP and the Swiss database. We downloaded disease gastric cancer targets from the GeneCards database and used the Venn diagram to identify common targets for disease and drugs. Then, we performed GO and KEGG pathway enrichment analyses, used the Cytoscape software to screen core targets and components, and constructed a drug-disease-target network. In addition, visual molecular docking and molecular dynamics simulation of targets and components with strong affinity were performed. Finally, we verified the effect of the drug on cell proliferation and metastasis using CCK8, clonal formation, and wound healing assays, and investigated the molecular mechanism by qRT-PCR. A total of 33 bioactive components were procured; 128 common targets for gastric cancer and drugs were screened. The GO and KEGG pathway enrichment analyses showed the PI3K-AKT pathway to be at the top. The core target AKT1 and the core component isorhamnetin exhibited the strongest molecular binding force and good binding stability. Compared to the control group, Weinaian capsule group inhibited gastric cancer cell proliferation and migration by down-regulating the expressions of PI3K and AKT. Weinaian capsule inhibited cell proliferation and metastasis by affecting the PI3K-AKT pathway in gastric cancer.

Macrophage-derived FN1 promotes peritoneal cavity metastasis of gastric cancer by inhibiting the Hippo signaling pathway via SDC4.

Elucidating the molecular mechanisms of the mongolian medicine Ana Gaqi Nari in gastric cancer treatment through a multi-omics-guided experimental validation.

Geographic dimensions of gastric cancer risk in western Honduras: A spatial ecological analysis.

The role of circular RNA in the occurrence and progression of gastric cancer: Emerging perspectives on its use as diagnostic and therapeutic biomarkers and therapeutic targets.

Tumor-derived C4BPA promotes macrophage M2-like polarization through C5a -C5aR1-STAT3 axis and drives gastric cancer progression.

Efficacy and safety of intraperitoneal paclitaxel-based regimens in patients with gastric cancer and peritoneal metastasis: A systematic review and meta-analysis.

Dioscin suppresses epithelial-mesenchymal transition in gastric cancer by upregulating Cx43 to inhibit the VEGFA/PI3K/Akt/mTOR pathway pathway.

Gastric cancer prognosis remains poor, and neoadjuvant chemotherapy (NAC) is not widely used in Japan. While docetaxel-based regimens have shown promise internationally, the biological basis of their efficacy is not fully understood. We performed a transcriptomic analysis of tumor sections from 24 patients with gastric cancer who received docetaxel plus S-1 (DS) or docetaxel with cisplatin plus S-1 (DCS) as NAC between 2011 and 2015. Our goal was to identify key biological differences between pathologically responsive and non-responsive groups. The non-responding group had a significantly worse prognosis (p=0.017) despite similar baseline patient characteristics. Their tumors were marked by enrichment of proliferation-related gene sets, and a low infiltration of CD8+ and CD4+ effector memory cells and dendritic cells. We found no difference in key immune pathways, such as interferon-γ and interferon-α response. A final key finding was the significantly lower expression of five genes, namely zinc finger protein 296 (ZNF296), RAS association domain family member 10 (RASSF10), exocyst complex component 3-like 1 (EXOC3L1), microtubule-associated tyrosine carboxypeptidase 2 (KIAA0895), and polypeptide N-acetylgalactosaminyltransferase 1 (GALNTL1), in the non-response group. Our study suggests that the lack of NAC response to DS/DCS therapy is associated with increased tumor proliferation, a poor antitumor immune response, and the reduced expression of these five genes (ZNF296, RASSF10, EXOC3L1, KIAA0895 and GALNTL1). These genes represent promising candidates for further investigation as biomarkers for predicting treatment efficacy and as novel therapeutic targets.

Core role of H19 LncRNA in gastric cancer: From tumor ecosystem reprogramming to precision therapy.

Telomere maintenance meets cancer metabolism: Mechanistic insights and clinical opportunities.

Trastuzumab deruxtecan: Redefining precision oncology across HER2-driven cancers.

Advancing electrochemical nanobiosensors for gastric cancer diagnostics: Engineering challenges and clinical integration toward mHealth applications.

Bufalin targeting METTL17 inhibits the occurrence and metastasis of oral cancer through JAK1/STAT3 signaling pathway.

Interpretable machine learning model using dual-energy CT for predicting adverse histopathological status in gastric cancer: A multicenter study

Integrating deep generative model with active learning for predicting immunotherapy responses in gastric cancer.

Electrochemical biosensing of Helicobacter pylori in gastrointestinal disease.